The subgroup analysis of intermediate-risk non-muscle invasive bladder cancer: Its effects on recurrence rates and intravesical treatment strategy

2019 ◽  
Vol 18 (11) ◽  
pp. e3588-e3591
Author(s):  
I. Selvi ◽  
E. Ozturk
Keyword(s):  
Bladder Cancer ◽  
Subgroup Analysis ◽  
Treatment Strategy ◽  
Invasive Bladder Cancer ◽  
Intermediate Risk ◽  
Recurrence Rates ◽  
Muscle Invasive Bladder Cancer ◽  
Intravesical Treatment ◽  
Muscle Invasive

scholarly journals Comparison of the EORTC and CUETO prognostic models in non-muscle-invasive bladder cancer

2018 ◽  
Vol 14 (2) ◽  
pp. 162-170
Author(s):  
A. D. Kaprin ◽  
O. I. Apolikhin ◽  
B. Ya. Alekseev ◽  
D. A. Roshchin ◽  
A. A. Kachmazov ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Treatment Strategy ◽  
Scoring Systems ◽  
Prognostic Models ◽  
Invasive Bladder Cancer ◽  
Molecular Characteristics ◽  
Muscle Invasive Bladder Cancer ◽  
European Organization ◽  
Genetic Characteristics ◽  
Muscle Invasive

Bladder cancer is one of the most common malignant diseases involving the urinary system. Accurate prediction of the disease course and outcome is crucial for choosing an appropriate treatment strategy in these patients. Currently, there are several prognostic models for predicting non-muscle invasive bladder cancer outcomes. The scoring systems developed by the European Organization for Research and Treatment of Cancer (EORTC) and the Spanish Urological Club for Oncological Treatment (CUETO) are the most widely used prognostic models for bladder cancer. Despite the undeniable merits of these scales, they need to be supplemented. Since the prognostic score has a direct impact on the treatment strategy, intensity and costs of postoperative follow-up, and outcome, its accuracy should be higher than it is now. Identifying the additional parameters that would increase the robustness of these models is one of the major challenges for researchers.The molecular and genetic characteristics of the tumor, that can be estimated after the first surgery, are probably the best candidates for this role. The main limitation of these prognostic models lies in the fact that they assess only morphological properties of the tumor, while the most important molecular characteristics are neglected. These scoring systems do not evaluate clinical factors, concomitant diseases, and iatrogenic complications occurring during the treatment of relapses. The assessment of molecular mechanisms and clinical characteristics underlying the development of non-muscle-invasive bladder cancer as well as identification of key molecular markers, that could complement the currently existing risk assessment models, are the most important goals for researchers dealing with bladder cancer. It will significantly improve predictive capabilities of these models, ensuring the choice of an optimal treatment strategy.

How well do we manage non-muscle invasive bladder tumors? A UK audit of real-life practices

2020 ◽  
Vol 87 (3) ◽  
pp. 142-148
Author(s):  
Petros Sountoulides ◽  
Wilbert Fana Mutomba ◽  
Emmanouil Bouras ◽  
Jieqi Lim ◽  
Andreas Bourdoumis ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Carcinoma In Situ ◽  
Real Life ◽  
Invasive Bladder Cancer ◽  
Detrusor Muscle ◽  
Bladder Tumors ◽  
Recurrence Rates ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive

Objective: The aim of this study was to assess the quality of TURBT (transurethral resection of bladder tumor) using surrogate parameters and evaluate adherence to the guidelines regarding the management of bladder tumors. Materials and methods: A clinical audit of all new diagnosis of bladder cancer was undertaken from January 2016 to January 2017. A total of 101 new bladder cancer cases were included. Surrogates of TURBT quality including presence of detrusor in the specimen, rate of re-TUR, presence of carcinoma in situ, and 3-month recurrence rates were analyzed. Adherence to guidelines regarding management of non-muscle invasive bladder cancer including time to re-TUR and utilization of single instillation chemotherapy was evaluated. Results: Absence of detrusor muscle in the specimen of the initial TURBT was noted in 22.8% of the cases. The chance of including muscle in the specimen was almost four-fold for tumors larger than 3 cm. A single instillation of intravesical chemotherapy following TURBT was administered in only 40% of eligible patients; 54.3% of patients had a re-TUR, the majority (61.3%) for high-grade non-muscle invasive bladder cancer on initial TURBT. Re-TUR was done on average 10 weeks after initial TURBT. The 3-month recurrence rate was 36.0% with larger tumors (>3 cm) being more prone to early recurrences. Early recurrences were not affected by intravesical instillations with bacillus Calmette–Guérin or mitomycin C although there was a positive association between the presence of carcinoma in situ on initial resection and early recurrences. Discussion and conclusion: One in two patients will have a re-TUR, and approximately one in two patients will have tumor on re-TUR. Single immediate chemotherapy instillations after TURBT are underutilized. The presence of carcinoma in situ on initial TURBT and tumor size were predictors of early recurrences.

scholarly journals Diabetic Metrics That Lead to Increased Recurrence Rates in Non-Muscle Invasive Bladder Cancer

2017 ◽  
Vol 225 (4) ◽  
pp. e50
Author(s):  
Tracy M. Downs ◽  
Timothy J. Rushmer ◽  
E. Jason Abel ◽  
Shivashankar Damodaran ◽  
Kyle A. Richards ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Invasive Bladder Cancer ◽  
Recurrence Rates ◽  
Muscle Invasive Bladder Cancer ◽  
Muscle Invasive
Sign in / Sign up

Export Citation Format

Share Document